Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapy

References

• WebersCABeckersHJNuijtsRMSchoutenJSPharmacological management of primary open-angle glaucoma: second-line options and beyondDrugs Aging200825972975918729546
   PubMed Web of Science ®Google Scholar
• BeidoeGMousaSACurrent primary open-angle glaucoma treatments and future directionsClin Ophthalmol201261699170723118520
   PubMedGoogle Scholar
• QuigleyHABromanATThe number of people with glaucoma worldwide in 2010 and 2020Br J Ophthalmol200690326226716488940
   PubMed Web of Science ®Google Scholar
• KwonYHFingertJHKuehnMHAlwardWLPrimary open-angle glaucomaN Engl J Med2009360111113112419279343
   PubMed Web of Science ®Google Scholar
• KassMAHeuerDKHigginbothamEJThe Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucomaArch Ophthalmol2002120670171312049574
   PubMed Web of Science ®Google Scholar
• van GestelAWebersCASeverensJLThe long-term outcomes of four alternative treatment strategies for primary open-angle glaucomaActa Ophthalmol2012901203122289192
   PubMed Web of Science ®Google Scholar
• AlexanderCLMillerSJAbelSRProstaglandin analog treatment of glaucoma and ocular hypertensionAnn Pharmacother200236350451111895065
   PubMed Web of Science ®Google Scholar
• HigginbothamEJConsiderations in glaucoma therapy: fixed combinations versus their component medicationsClin Ophthalmol201041920169043
   PubMedGoogle Scholar
• RobinALNovackGDCovertDWCrockettRSMarcicTSAdherence in glaucoma: objective measurements of once-daily and adjunctive medication useAm J Ophthalmol2007144453354017686450
   PubMed Web of Science ®Google Scholar
• ChraiSSMakoidMCEriksenSPRobinsonJRDrop size and initial dosing frequency problems of topically applied ophthalmic drugsJ Pharm Sci19746333333384820359
   PubMed Web of Science ®Google Scholar
• BarnebeyHSOrengo-NaniaSFlowersBEThe safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solutionAm J Ophthalmol200514011715990081
   PubMed Web of Science ®Google Scholar
• SchumanJSKatzGJLewisRAEfficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertensionAm J Ophthalmol2005140224225016086946
   PubMed Web of Science ®Google Scholar
• HughesBABacharachJCravenERA three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to travoprost 0.004% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open angle glaucoma or ocular hypertensionJ Glaucoma200514539239916148589
   PubMed Web of Science ®Google Scholar
• GrossRLSullivanEKWellsDTMallickSLandryTABergaminiMVPooled results of two randomized clinical trials comparing the efficacy and safety of travoprost 0.004%/timolol 0.5% in fixed combination versus concomitant travoprost 0.004% and timolol 0.5%Clin Ophthalmol20071331732219668487
   PubMedGoogle Scholar
• TomicMKastelanSMetez SoldoKSalopek-RabaticJInfluence of BAK-preserved prostaglandin analog treatment on the ocular surface health in patients with newly diagnosed primary open-angle glaucomaBiomed Res Int2013201360378223971041
   PubMed Web of Science ®Google Scholar
• KatzGSpringsCLCravenERMontecchi-PalmerMOcular surface disease in patients with glaucoma or ocular hypertension treated with either BAK-preserved latanoprost or BAK-free travoprostClin Ophthalmol201041253126121151330
   PubMedGoogle Scholar
• DuoTrav® (travoprost 0.004%/timolol 0.5%)Full Prescribing InformationSurrey, UKAlcon Laboratories (UK) Ltd2013
   Google Scholar
• KitazawaYSmithPSasakiNKotakeSBaeKIwamotoYTravoprost 0.004%/timolol 0.5%-fixed combination with and without benzalkonium chloride: a prospective, randomized, doubled-masked comparison of safety and efficacyEye (Lond)20112591161116921701528
   PubMed Web of Science ®Google Scholar
• European Glaucoma SocietyTerminology and Guidelines for Glaucoma3rd edSavona, ItalyDogma S.r.l.2008
   Google Scholar
• BrandtJDCantorLBKatzLJBimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertensionJ Glaucoma200817321121618414107
   PubMed Web of Science ®Google Scholar
• PfennigsdorfSde JongLMakkSA combined analysis of five observational studies evaluating the efficacy and tolerability of bimatoprost/timolol fixed combination in patients with primary open-angle glaucoma or ocular hypertensionClin Ophthalmol201371219122523814459
   PubMedGoogle Scholar
• CentofantiMOddoneFGandolfiSComparison of travoprost and bimatoprost plus timolol fixed combinations in open-angle glaucoma patients previously treated with latanoprost plus timolol fixed combinationAm J Ophthalmol2010150457558020688314
   PubMed Web of Science ®Google Scholar
• ScherzerMLLiehneovaINegreteFJSchnoberDTravoprost 0.004%/timolol 0.5% fixed combination in patients transitioning from fixed or unfixed bimatoprost 0.03%/timolol 0.5%Adv Ther201128866167021773673
   PubMed Web of Science ®Google Scholar
• ArendKORaberTObservational study results in glaucoma patients undergoing a regimen replacement to fixed combination travoprost 0.004%/timolol 0.5% in GermanyJ Ocul Pharmacol Ther200824441442018665813
   PubMed Web of Science ®Google Scholar
• PfeifferNScherzerMLMaierHSafety and efficacy of changing to the travoprost/timolol maleate fixed combination (DuoTrav) from prior mono- or adjunctive therapyClin Ophthalmol2010445946620505839
   PubMedGoogle Scholar
• BaudouinCLabbeALiangHPaulyABrignole-BaudouinFPreservatives in eyedrops: the good, the bad and the uglyProg Retin Eye Res201029431233420302969
   PubMed Web of Science ®Google Scholar
• De Saint JeanMBrignoleFBringuierAFBauchetAFeldmannGBaudouinCEffects of benzalkonium chloride on growth and survival of Chang conjunctival cellsInvest Ophthalmol Vis Sci199940361963010067965
   PubMed Web of Science ®Google Scholar
• GuenounJMBaudouinCRatPPaulyAWarnetJMBrignole-BaudouinFIn vitro study of inflammatory potential and toxicity profile of latanoprost, travoprost, and bimatoprost in conjunctiva-derived epithelial cellsInvest Ophthalmol Vis Sci20054672444245015980234
   PubMed Web of Science ®Google Scholar